MetaCap

iRhythm Holdings Inc. (IRTC)

NASDAQ: IRTCHealth CareMedical/Dental InstrumentsUSD

94.72+0.48 (+0.51%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IRTC stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.17
52-week range
82.85 – 192.47
Day range
93.01 – 96.77
Volume / Avg
875.30K / 682.68K
Beta
—

52-week range

$82.85$192.47

IRTC stock today

iRhythm (IRTC) closed at $94.72 on Nov 20, up 0.51% (+$0.48), versus the S&P 500's 3.70% decline. At this level, IRTC sits near the bottom of its 52-week range of $82.85 to $192.47: 50.8% below the high, set on Nov 26, 2025 and 14.3% above the low. IRTC is down 46.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.7%.

iRhythm has posted a net loss over the last twelve months (EPS of -$1.17), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About iRhythm

Company profile

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data.

Industry
Medical/Dental Instruments
CEO
Mr. Quentin S. Blackford
Headquarters
San Francisco, CA
Employees
2,400
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, iRhythm generated $747.1 million in revenue, up 26.2% from fiscal 2024, its 11th consecutive year of revenue growth. iRhythm reported a net loss of $44.6 million, compared with a loss of $113.3 million a year earlier. Gross margin was 70.6% (up from 68.9%) and operating margin -7.7%.

iRhythm annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$747.14M$591.84M$492.68M$410.92M$322.82M
Growth+26.24%+20.13%+19.90%+27.29%+21.74%
Net income$-44.55M$-113.29M$-123.41M$-116.16M$-101.36M
EPS (diluted)$-1.39$-3.63$-4.04$-3.88$-3.46

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$153.27+61.81%

  • Strong buy 3
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $120.00High $206.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.06 vs $0.02
Surprise
-400.00%

IRTC news

All IRTC news

iRhythm peers

Health Care sector
IRTC peer companies
CompanyPrice% ChgMarket capCompare
PLSEPulse Biosciences Inc45.55+2.57%$3.35Bvs IRTC
ATRCAtriCure Inc.55.39+2.37%$2.82Bvs IRTC
NVSTEnvista Holdings Corporation22.91-1.55%$3.67Bvs IRTC
UFPTUFP Technologies Inc.290.85-2.70%$2.25Bvs IRTC
HTFLHeartflow Inc.46.69+4.62%$4.10Bvs IRTC
STVNStevanato Group S.p.A.15.65-1.76%$4.27Bvs IRTC
ICUIICU Medical Inc.172.52-1.84%$4.31Bvs IRTC
MMEDMiniMed Group Inc.16.01-1.54%$4.50Bvs IRTC

Indexes, lists and sector

iRhythm stock FAQ

What is iRhythm's stock price today?

IRTC last traded at $94.72 as of Nov 20, 4:00 PM EST, up 0.51% on the day. Prices are delayed at least 15 minutes.

Who is iRhythm's CEO?

Mr. Quentin S. Blackford is the chief executive officer of iRhythm Holdings Inc., which has about 2,400 employees.

What is the IRTC 52-week high?

The 52-week high for IRTC is $192.47 and the 52-week low is $82.85. The stock is currently 50.8% below its high.

Compare IRTC